---
document_datetime: 2025-12-11 15:25:42
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pifeltro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pifeltro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.166586
conversion_datetime: 2025-12-31 01:44:28.247591
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pifeltro

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number                    | Scope                                                                                                    | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000268084 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, | 16/10/2025                          |                                             | SmPC and PL                      | As a result of this variation, section 4.8 of the SmPC was updated with the addition of 'hepatitis', with frequency 'unknown'. The Package Leaflet (PL) was |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to add hepatitis as adverse reaction associated with doravirine used in combination with other antiretrovirals with frequency unknown based on post-marketing data, literature and data from clinical trials; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.   | updated accordingly For more information, please refer to the Summary of Product Characteristics.   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|